We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Name | Symbol | Market | Type |
|---|---|---|---|
| GSK plc | NYSE:GSK | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.21 | -0.52% | 39.80 | 40.005 | 39.745 | 39.97 | 569,709 | 15:09:47 |
From Jul 2021 to Jul 2024
By Jaime Llinares Taboada
GlaxoSmithKline PLC said Friday that the European Commission has approved its sotrovimab antibody for the early treatment of Covid-19.
The pharmaceutical company and Vir Biotechnology Inc. said the EC, the executive branch of the European Union, has granted marketing authorization.
The product is now approved for the treatment of adults and adolescents at risk of progressing to severe Covid-19.
In July, GSK and Vir reached a deal with the EU to supply up to 220,000 doses of sotrovimab.
Write to Jaime Llinares Taboada at jaime.llinares@wsj.com; @JaimeLlinaresT
(END) Dow Jones Newswires
December 17, 2021 08:19 ET (13:19 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year GSK Chart |
1 Month GSK Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
